Rejuvenating sirtuins: The rise of a new family of cancer drug targets

Santina Bruzzone, Marco Daniele Parenti, Alessia Grozio, Alberto Ballestrero, Inga Bauer, Alberto Del Rio, Alessio Nencioni

Research output: Contribution to journalArticle

Abstract

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.

Original languageEnglish
Pages (from-to)614-623
Number of pages10
JournalCurrent Pharmaceutical Design
Volume19
Issue number4
Publication statusPublished - 2013

Keywords

  • Cancer
  • Drug design
  • Drug discovery
  • Epigenetics
  • Sirtuin modulators

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Rejuvenating sirtuins: The rise of a new family of cancer drug targets'. Together they form a unique fingerprint.

  • Cite this

    Bruzzone, S., Parenti, M. D., Grozio, A., Ballestrero, A., Bauer, I., Del Rio, A., & Nencioni, A. (2013). Rejuvenating sirtuins: The rise of a new family of cancer drug targets. Current Pharmaceutical Design, 19(4), 614-623.